All In Biotech

Drug Trial Radar · NCT06374394

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

A Phase 3, Open-label, Randomized, Controlled Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-Administered With a COVID-19 mRNA Vaccine (Omicron XBB.1.5) in Adults Aged 50 Years and Above

Last checked: Nov 20, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 841 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

841

Actual

Start

Apr 29, 2024

Primary completion

Nov 1, 2024

Study completion Mar 31, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.

  • COVID-19 mRNA vaccineBiological

    1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA VaccinationTime frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
  2. Adjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA VaccinationTime frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
  3. Adjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA VaccinationTime frame: At 1 month post-COVID-19 mRNA vaccine dose administration (at Day 31 for both groups)

Locations

24 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Evansville, Indiana

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    North Charleston, South Carolina

  • GSK Investigational Site

    Newport News, Virginia

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Kluisbergen, Belgium

  • GSK Investigational Site

    Mechelen, Belgium

  • GSK Investigational Site

    Breda, Netherlands

  • GSK Investigational Site

    Enschede, Netherlands

  • GSK Investigational Site

    Utrecht, Netherlands

  • GSK Investigational Site

    Zutphen, Netherlands

  • GSK Investigational Site

    A Coruña, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Boadilla Del Monte Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.